Latest On Bayer Aktiengesellschaft (BAYRY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-04-29 05:56 EST | Dividend | A dividend of $0.03 has been announced on Apr 2, 2024. It will be paid May 13, 2024 with an ex-dividend date of Apr 29, 2024. | Neutral |  |
| 2023-05-18 13:16 EST | News | Bayer's kidney disease drug Kerendia gets Chinese regulator nod for expanded use | N/A | |
| 2023-05-18 00:06 EST | News | Bayer Aktiengesellschaft 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-17 10:29 EST | News | Cancer-focused Boundless Bio closes $100M funding led by Bayer, RA Capital | N/A | |
| 2023-05-16 21:01 EST | News | Bayer Agriscience, Shades Of Corteva | N/A | |
About Bayer Aktiengesellschaft (BAYRY):
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protect read more...ion products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
General
- Name Bayer Aktiengesellschaft
- Symbol BAYRY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 95,955
- Last Split Factor4:1
- Last Split Date2017-09-20
- Fiscal Year EndDecember
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.bayer.com
Valuation
- Trailing PE 8.62
- Forward PE 9.34
- Price/Sales (Trailing 12 Mt.) 1.26
- Price/Book (Most Recent Quarter) 1.72
- Enterprise Value Revenue 2.34
- Enterprise Value EBITDA 10.06
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -25%
- Return on Assets 4%
- Return on Equity -40%
- Earnings Per Share $1.84
- Revenue Per Share $0
- Gross Profit 25.67 billion
- Quarterly Earnings Growth -7%
Highlights
- Market Capitalization 61.8 billion
- PEG Ratio 21.72
- Analyst Target Price $17.2
- Book Value Per Share $14.93
Share Statistics
- Shares Outstanding 3.93 billion
- Shares Float 3.93 billion
- % Held by Insiders <1%
- % Held by Institutions 0.18%
- Shares Short Prior Month 611188
Technicals
- Beta 1.33
- 52 Week High $20.77
- 52 Week Low $11.65
- 50 Day Moving Average 16.01
- 200 Day Moving Average 14.97
Dividends
- Forward Annual Dividend Rate $0.76
- Forward Annual Dividend Yield 4.84%
- Payout Ratio 42%
- Dividend Date 2020-05-14
- ExDividend Date 2020-04-29
- Dividend Per Share $3.26
- Dividend Yield 0%
Bayer Aktiengesellschaft (BAYRY) Dividend Calendar:
BAYRY's last dividend payment was made to shareholders on May 14, 2020.
Bayer Aktiengesellschaft pays out 42% of its earnings out as a dividend.
Bayer Aktiengesellschaft (BAYRY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Bayer Aktiengesellschaft (BAYRY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Bayer Aktiengesellschaft (BAYRY) Chart:
Bayer Aktiengesellschaft (BAYRY) News:
Below you will find a list of latest news for Bayer Aktiengesellschaft (BAYRY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bayer Aktiengesellschaft (BAYRY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Bayer Aktiengesellschaft (BAYRY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2018-01-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2016-11-25 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-11-16 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-11-15 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-11-10 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-11-09 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-10-31 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-10-28 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-10-18 | 3 (Initial statement of beneficial ownership of securities) | |
| 2016-10-17 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-10-13 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-10-12 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-10-11 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-09-21 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-09-20 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-09-20 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-09-16 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-09-14 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-09-14 | DFAN14A (Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material) | |
| 2016-09-06 | SC TO-C (Written communication relating to an issuer or third party) | |
Bayer Aktiengesellschaft (BAYRY) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bayer Aktiengesellschaft (BAYRY). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: < 1%
Institutional Ownership: 18%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-01-05 | AKTIENGESELLSCHAFT BAYER | 10% Share Holder | Buy | 527,472.00 | 22.75 | 11,999,988.00 | 5,632,802.00 | |